Kodiak Sciences (NASDAQ:KOD) Stock Price Target Raised at HC Wainwright

Key Points

• HC Wainwright raised Kodiak Sciences’ price target from $58 to $96 and maintained a “buy” rating, implying about 9.5% upside from the reported share price.
• Kodiak shares surged 171% to $87.67 on unusually heavy volume, reaching a new 12-month high and lifting the company’s market capitalization to approximately $5.51 billion.
• Analyst sentiment remains mixed but leans positive: five analysts rate the stock a Buy, one a Hold and one a Sell, producing a “Moderate Buy” consensus and a $63.17 average price target. The company also missed its latest quarterly EPS estimate, reporting a loss of $1.05 per share versus expectations of $0.96.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) had its target price lifted by equities research analysts at HC Wainwright from $58.00 to $96.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's target price points to a potential upside of 9.50% from the company's current price.

Other analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. raised their price objective on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an "overweight" rating in a research note on Monday, August 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of Kodiak Sciences in a research report on Friday, July 10th. Wall Street Zen cut shares of Kodiak Sciences from a "sell" rating to a "strong sell" rating in a report on Saturday. Finally, The Goldman Sachs Group started coverage on shares of Kodiak Sciences in a research report on Thursday. They set a "neutral" rating and a $36.00 price target for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $63.17.

Kodiak Sciences Stock Up 171.0%

Shares of Kodiak Sciences stock traded up $55.32 during trading on Monday, reaching $87.67. The company's stock had a trading volume of 24,168,461 shares, compared to its average volume of 963,897. Kodiak Sciences has a 12-month low of $10.94 and a 12-month high of $87.83. The company has a market capitalization of $5.51 billion, a P/E ratio of -20.75 and a beta of 2.18. The business has a 50 day moving average price of $38.31 and a 200-day moving average price of $37.34.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by ($0.09). Research analysts predict that Kodiak Sciences will post -3.89 EPS for the current fiscal year.

Institutional Investors Weigh In On Kodiak Sciences

A number of large investors have recently added to or reduced their stakes in KOD. Arizona State Retirement System lifted its stake in Kodiak Sciences by 6.9% in the 2nd quarter. Arizona State Retirement System now owns 8,533 shares of the company's stock valued at $332,000 after buying an additional 554 shares in the last quarter. V Square Quantitative Management LLC acquired a new position in shares of Kodiak Sciences in the first quarter worth $26,000. Westfuller Advisors LLC purchased a new stake in shares of Kodiak Sciences in the first quarter valued at $26,000. EverSource Wealth Advisors LLC boosted its stake in shares of Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company's stock valued at $28,000 after acquiring an additional 916 shares during the last quarter. Finally, KBC Group NV purchased a new stake in Kodiak Sciences during the 1st quarter worth about $39,000. 89.06% of the stock is owned by institutional investors and hedge funds.

More Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: DAYBREAK produced positive results for Zenkuda and tabirafusp-ted, also known as KSI-501, in patients with wAMD. The results validate Kodiak’s lead ophthalmology candidates and provide a major clinical milestone. Kodiak Sciences Reports Positive Phase 3 DAYBREAK Results
• Positive Sentiment: Management said Zenkuda performed on par with Regeneron’s blockbuster Eylea, strengthening the candidate’s potential competitive and commercial positioning in the large wAMD market. Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
• Positive Sentiment: Following the trial success, Kodiak plans to submit Zenkuda for regulatory approval. That creates a clear next catalyst, although approval and eventual commercialization remain subject to regulatory review. Kodiak Sciences Stock Pops After Eye-Disease Drugs Pass Key Trial
• Neutral Sentiment: The sharp rally has pushed Kodiak to a new 12-month high and attracted unusually heavy trading activity, indicating strong investor interest but also increasing the risk of volatility and profit-taking.
• Neutral Sentiment: Goldman Sachs recently initiated research coverage on Kodiak, potentially increasing institutional visibility; the available report does not provide a specific rating or price target. Kodiak Sciences Research Coverage Started at Goldman Sachs

About Kodiak Sciences

Kodiak Sciences Inc NASDAQ: KOD is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company's research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.